Live Investor Briefing – Prescient Therapeutics

Prescient Therapeutics (ASX: PTX)

Live Investor Briefing

Register for an Upcoming Webcast

Please join us for a special ‘OmniCAR Explainer’ session with Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Dr Rebecca Lim, Director of Scientific Affairs.

In the session, we will:

  • Provide an overview into the amazing field of CAR-T, and how Prescient’s next gen CAR-T platform, OmniCAR, is seeking to take this burgeoning cancer field to the next level.
  • Step through the new preclinical data, which demonstrates key OmniCAR features in next gen CAR-Ts, including control and flexibility which is not possible with current generation CAR-T therapies.

This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.

Book Your Spot

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.


Steven Yatomi-Clarke (Speak feature)

Steven Yatomi Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.

Steven Yatomi-Clarke (Speak feature)

Rebecca Lim, PhD

Director of Scientific Affairs

Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.